Scarica l'app Stockscreener
0.4354
3.64%
0.0153
Dopo l'orario di chiusura:
.45
0.0146
+3.35%
Shuttle Pharmaceuticals Holdings Inc Borsa (SHPH) Ultime notizie
This Md. biotech wants to get a cancer treatment to patients. It just tapped an industry outsider as co-CEO. - Washington Business Journal
Shuttle Pharma announces $5.75 million stock offering - Investing.com
Shuttle Pharma Secures Critical $5.75M Funding for Revolutionary Cancer Radiation Therapy - StockTitan
4 Artificial Intelligence (AI) Stocks Worth Buying in the Tech Sell-Off - The Globe and Mail
Lucid Group (LCID) Prepares to Sink Into Penny Stock Territory - The Globe and Mail
1 Large-Cap Stock with Solid Fundamentals and 2 to Avoid - The Globe and Mail
Shuttle Pharma appoints new interim co-CEO - Investing.com
Shuttle Pharmaceuticals appoints Christopher Cooper as interim Co-CEO - TipRanks
Shuttle Pharma Announces Appointment Of Christopher Cooper As Interim Co-CEO To Enhance Business Activities - Marketscreener.com
Shuttle Pharmaceuticals Appoints Christopher Cooper as Co-CEO - TipRanks
Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities - GlobeNewswire
Shuttle Pharma Strengthens Leadership: New Co-CEO to Accelerate Growth While Phase 2 Trial Advances - StockTitan
SHPH stock touches 52-week low at $0.5 amid sharp annual decline - Investing.com Australia
SHPH stock touches 52-week low at $0.5 amid sharp annual decline By Investing.com - Investing.com South Africa
Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected - The Globe and Mail
Shuttle Pharmaceuticals Holdings Offers Up To 10,000,000 Shares Of Common Stock -March 05, 2025 at 07:42 am EST - Marketscreener.com
Amendment: SEC Form S-1/A filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Enters Revolving Loan Agreement - TipRanks
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement -February 28, 2025 at 05:26 pm EST - Marketscreener.com
Shuttle Pharmaceuticals Holdings Enters $2 Million Revolving Loan Agreement - TradingView
3 Reasons to Sell RH and 1 Stock to Buy Instead - The Globe and Mail
SEC Form 424B3 filed by Shuttle Pharmaceuticals Holdings Inc. - Quantisnow
Shuttle Pharmaceuticals Amends Agreement with Alto Fund By Investing.com - Investing.com Australia
Shuttle Pharmaceuticals Amends Agreement with Alto Fund - Investing.com
SHPH stock touches 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa
SHPH stock touches 52-week low at $0.57 amid market challenges - Investing.com
Shuttle Pharma advances glioblastoma trial, expands diagnostics - Investing.com India
Shuttle Pharma advances glioblastoma trial, expands diagnostics By Investing.com - Investing.com South Africa
Shuttle Pharmaceuticals Holdings, Inc. Reports Progress on Phase 2 Trial and Diagnostic Advancements in Annual Update - Nasdaq
Shuttle Pharma Provides Corporate Update and Reports 2024 Results - GlobeNewswire
Can Shuttle Pharma's Glioblastoma Treatment Breakthrough Deliver Returns? CEO Bets $237K - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Why Five9 Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Contrasting Shuttle Pharmaceuticals (NASDAQ:SHPH) and Insmed (NASDAQ:INSM) - Defense World
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe - NewsBreak
Norwegian Air Shuttle ASA (NWARF) Expected to Announce Earnings on Thursday - Defense World
Badger Meter (BMI) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Cadre Holdings, Inc. (NYSE: CDRE) Enters Share Purchase Agreement with Carr’s Group PlcOn January 15, 2025, Cadre Holdings, Inc. (the “Company”) disclosed that it has entered into a Share Purchase Agreement with Carr’s Group Plc, selling all of the i - Defense World
GAN Limited Notifies of Non-Compliance with Nasdaq Listing RulesOn January 14, 2025, GAN Limited (NASDAQ: GAN) received a written notice from The Nasdaq Stock Market LLC stating that the company was not in compliance with Listing Rules 5620(a) a - Defense World
**Monster Beverage Corporation to Host Investor Meeting for Business Update**** - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma hits 25% mark in glioblastoma trial By Investing.com - Investing.com Australia
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - Marketscreener.com
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - The Manila Times
3.49%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):